{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:58:46Z","timestamp":1773183526894,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by Eisai Ltd, UK, and by the NIHR Leeds Clinical Research Facility."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41416-018-0366-5","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:04:08Z","timestamp":1550621048000},"page":"579-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A phase 1b\/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine"],"prefix":"10.1038","volume":"120","author":[{"given":"Chris","family":"Twelves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Anthoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio I.","family":"Savulsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Reyderman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cresti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Semiglazov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanta","family":"Timcheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishtiaq","family":"Zubairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. R. Jeffry","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"366_CR1","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","volume":"25","author":"F Cardoso","year":"2014","unstructured":"Cardoso, F. et al. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Ann. Oncol. 25, 1871\u20131888 (2014).","journal-title":"Ann. Oncol."},{"key":"366_CR2","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","volume":"32","author":"AH Partridge","year":"2014","unstructured":"Partridge, A. H. et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 32, 3307\u20133329 (2014).","journal-title":"J. Clin. Oncol."},{"key":"366_CR3","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Breast Cancer. Version 3.2015, \n                    http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\n                    \n                   (accessed 5 November 2015)."},{"key":"366_CR4","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov, G. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64, 5760\u20135766 (2004).","journal-title":"Cancer Res."},{"key":"366_CR5","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013\u20131021 (2001).","journal-title":"Cancer Res."},{"key":"366_CR6","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","volume":"21","author":"NF Dybdal-Hargreaves","year":"2015","unstructured":"Dybdal-Hargreaves, N. F., Risinger, A. L. & Mooberry, S. L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin. Cancer Res. 21, 2445\u20132452 (2015).","journal-title":"Clin. Cancer Res."},{"key":"366_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi, Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 105, 1334\u20131342 (2014).","journal-title":"Cancer Sci."},{"key":"366_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida, T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br. J. Cancer 110, 1497\u20131505 (2014).","journal-title":"Br. J. Cancer"},{"key":"366_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes, J. et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377, 914\u2013923 (2011).","journal-title":"Lancet"},{"key":"366_CR10","unstructured":"Kaufman, P. A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 33, 594\u2013601 (2015)."},{"key":"366_CR11","doi-asserted-by":"publisher","unstructured":"Twelves, C. et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl). 10, 77\u201384 (2016). \n                    https:\/\/doi.org\/10.4137\/BCBCR.S39615\n                    \n                  .","DOI":"10.4137\/BCBCR.S39615"},{"key":"366_CR12","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy, J. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol. 20, 2812\u20132823 (2002).","journal-title":"J. Clin. Oncol."},{"key":"366_CR13","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","volume":"92","author":"JL Blum","year":"2001","unstructured":"Blum, J. L. et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92, 1759\u20131768 (2001).","journal-title":"Cancer"},{"issue":"Suppl 6","key":"366_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0959-8049(14)70172-8","volume":"50","author":"M Asano","year":"2014","unstructured":"Asano, M. et al. Broad-spectrum preclinical combination activity of eribulin combined with various anticancer agents in human breast cancer, lung cancer, ovarian cancer, and melanoma xenograft models [abstract]. Eur. J. Cancer 50(Suppl 6), 20 (2014). (abstract P040).","journal-title":"Eur. J. Cancer"},{"key":"366_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1634\/theoncologist.2011-0281","volume":"17","author":"JA O\u2019Shaughnessy","year":"2012","unstructured":"O\u2019Shaughnessy, J. A. et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist 17, 476\u2013484 (2012).","journal-title":"Oncologist"},{"key":"366_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"366_CR17","unstructured":"Desjardins, C. et al. A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 875, 373\u2013382 (2008)."},{"key":"366_CR18","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","volume":"27","author":"LT Vahdat","year":"2009","unstructured":"Vahdat, L. T. et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 27, 2954\u20132961 (2009).","journal-title":"J. Clin. Oncol."},{"key":"366_CR19","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","volume":"28","author":"J Cortes","year":"2010","unstructured":"Cortes, J. et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 28, 3922\u20133928 (2010).","journal-title":"J. Clin. Oncol."},{"key":"366_CR20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1470-2045(11)70045-6","volume":"12","author":"LJ Oostendorp","year":"2011","unstructured":"Oostendorp, L. J., Stalmeier, P. F., Donders, A. R., van der Graaf, W. T. & Ottevanger, P. B. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol. 12, 1053\u20131061 (2011).","journal-title":"Lancet Oncol."},{"key":"366_CR21","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1023\/A:1012281104865","volume":"12","author":"JA O\u2019Shaughnessy","year":"2001","unstructured":"O\u2019Shaughnessy, J. A. et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer. Ann. Oncol. 12, 1247\u20131254 (2001).","journal-title":"Ann. Oncol."},{"key":"366_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","volume":"14","author":"P Reichardt","year":"2003","unstructured":"Reichardt, P. et al. Multicenter phase II study of oral capecitabine (Xeloda\u00ae) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol. 14, 1227\u20131233 (2003).","journal-title":"Ann. Oncol."},{"key":"366_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clbc.2015.07.007","volume":"16","author":"JW Smith 2nd","year":"2016","unstructured":"Smith, J. W. 2nd et al. Phase II, multicenter, single-arm, feasibility study of eribulin combined with capecitabine for adjuvant treatment in estrogen receptor-positive, early-stage breast cancer. Clin. Breast Cancer 16, 31\u201337 (2016).","journal-title":"Clin. Breast Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0366-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0366-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0366-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:04Z","timestamp":1684616644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0366-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0366-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"26 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C. Twelves has received honoraria from Roche, Eisai, AstraZeneca, Nektar, Pierre Fabre, and Pfizer. C.I.S., M.G., and L.R. are employees of Eisai Inc. R.P. has received honoraria from Roche, Bristol-Myers Squibb, AstraZeneca, Bayer, Clovis, Vertex, Astex, Novartis, Karus Therapeutics, Mission Therapeutics, and MSD. T.R.J.E. has received research funding from AstraZeneca, Celgene, Eisai, GSK, Roche, Basilea, e-Therapeutics, Immunocore, Vertex, Merck, Daiichi Sankyo, and Bristol-Myers Squibb; has received honoraria from Bristol-Myers Squibb; worked in a consulting or advisory role for Bristol-Myers Squibb, Baxter, Karus Therapeutics, and Eisai; and has received travel and accommodation expenses from, and participated in speakers\u2019 bureaus for, Bristol-Myers Squibb and Celgene. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was supported by the National Institute for Health Research (NIHR) Leeds Clinical Research Facility and by Eisai Ltd, UK. Investigators in Leeds, Newcastle, and Glasgow are supported by the Experimental Cancer Medicine Centre (ECMC) funding from Cancer Research UK, NIHR support from the Department of Health (England), and the Chief Scientist\u2019s Office (Scotland). Editorial support was provided by Oxford PharmaGenesis, Inc, and was funded by Eisai Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The data in this publication are commercially confidential. Data requests should be made to the Corresponding Author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"As stated in the article, this study was conducted in accordance with national and local Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by the relevant Institutional Review Board ethics committees. All patients provided written informed consent prior to participating in any study-specific procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No patient personal identifying data or images are included in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}